Antibodies against cytokeratin 8/18 in a patient with de novo autoimmune hepatitis after living-donor liver transplantation

Liver Transplantation

Volumn 11, Issue 5, 2005, Pages 504-507

  Inui, Ayano ^a   Sogo, Tsuyoshi ^a   Komatsu, Haruki ^b   Miyakawa, Hiroshi ^c   Fujisawa, Tomoo ^a  

^a International University of Health and Welfare   (Japan)

^b NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^c TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AZATHIOPRINE; CHELATING AGENT; CYTOKERATIN 18 ANTIBODY; CYTOKERATIN 8 ANTIBODY; CYTOKERATIN ANTIBODY; FLUCONAZOLE; ITRACONAZOLE; METHYLPREDNISOLONE; PREDNISOLONE; TACROLIMUS; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; AUTOIMMUNE HEPATITIS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISORDERS OF AMINO ACID AND PROTEIN METABOLISM; DRUG PULSE THERAPY; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; IMMUNOPATHOGENESIS; LIVER CELL; LIVER FIBROSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LIVING DONOR; MALE; MYCOSIS; POSTOPERATIVE PERIOD; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; WILSON DISEASE;

ADOLESCENT; ADULT; AUTOANTIBODIES; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HEPATITIS, AUTOIMMUNE; HEPATOCYTES; HUMANS; KERATINS; LIVER FAILURE; LIVER TRANSPLANTATION; LIVING DONORS; MALE; POSTOPERATIVE COMPLICATIONS;

EID: 18944406142     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1002/lt.20404     Document Type: Article

References (25)

1. Kerkar N, Hadzic N, Davis ET, Portmann B, Donaldson PT, Rela M, et al. De-novo autoimmune hepatitis after liver transplantation. Lancet 1998;351:409-413.
2. Andres S, Casamayou L, Sempoux C, Burlet M, Reding R, Bernard Ott J, et al. Posttransplant immune hepatitis in pediatric liver transplant recipients: incidence and maintenance therapy with azathioprine. Transplantation 2001;72:262-272.
3. Hernandez HM, Kovatik P, Whitington PF, Alonso EM. Autoimmune hepatitis as a late complication of liver transplantation. J Pediatr Gastroenterol Nutr 2001;32:131-136.
4. Heneghan MA, Portmann BC, Norris SM, Williams R, Muiesan P, Rela M, et al. Graft dysfunction mimicking autoimmune hepatitis following liver transplantation in adults. Hepatology 2001;34:464-470.
5. Gupta P, Hart J, Millis JM, Cronin D, Brandy L. De novo hepatitis with autoimmune antibodies and atypical histology. Transplantation 2001;71:664-668.
6. Salcedo M, Vaquero J, Banares R, Rodriguez-Mahou M, Alvarez E, Vicario JL, et al. Response to steroids in de novo autoimmune hepatitis after liver transplantation. Hepatology 2002;35:349-356.
7. Hadzic N, Ma Y, Srinivasan R, Cheeseman P, Mieli-Vergani G, Vergani D. Possible predictive and diagnostic role of anti-SLA antibodies in de novo autoimmune hepatitis after liver transplantation. Hepatology 2003;38:364A.
8. Aguilera I, Wichmann J, Sousa JM, Bernardos A, Franco E, Gracia-Lozano JR, Nunez-Roldan A. Antibodies against glutathione S-transferase T1 (GSTT1) in patients with de novo immune hepatitis following liver transplantation. Clin Exp Immunol 2001;126:535-539.
9. Miyakawa H, Kawashima Y, Kitazawa E, Kawaguchi N, Kato T, Kikuchi K, et al. Low frequency of anti-SLA/LP autoantibody in Japanese adult patients with autoimmune liver diseases: analysis with recombinant antigen assay. J Autoimmun 2003;21:77-82.
10. Alvares F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, et al. International Autoimmune Hepatitis Group Reports: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31:929-938.
11. International Panel. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997;25:658-663.
12. D'Antiga L, Dhawan A, Portmann B, Francavilla R, Rela M, Heaton N, Mieli-Vergani G. Late cellular rejection in paediatric liver transplantation: aetiology and outcome. Transplantation 2002;73:80-84.
13. Komatsu H, Inui A, Fujisawa T, Sogo T, Miyagawa. Y, Inui M, et al. Severe late acute allograft rejection in a child after living-related auxiliary partial orthotopic liver transplantation for orhithine transcarbamylase deficiency. Clin Transplantation 1999;13:300-304.
14. Miyagawa AH, Haga H, Egawa H, Hashimoto Y, Sakurai T, Minamiguchi S, et al. Outcome and risk factors of de novo autoimmune hepatitis in living-donor liver transplantation. Transplantation 2004;78:128-135.
15. Van Eyken P, Desmet VJ. Cytokeratins and the liver. Liver 1993;13:113-122.
16. Abe M, Oshima RG. A single human keratin 18 gene is expressed in diverse epithelial cells of transgenic mice. J Cell Biol 1990; 111:1197-1206.
17. Ku NO, Michie S, Oshima RG, Omary MB. Chronic hepatitis, hepatocytes fragility, and increased soluble phsphoglycokeratins in transgenic mice expressing a keratin 18 conserved arginine mutant. J Cell Biol 1995;131:1303-1314.
18. Ku NO, Michie SA, Soetikno RM, Resurreccion EZ, Broome RL, Oshima RG, Omary MB. Susceptibility to hepatotoxicity in transgenic mice that express a dominant-negative human keratin 18 mutant. J Clin Invest 1996;98:1034-1046.
19. Toivola DM, Omary MB, Ku NO, Peltola O, Baribault H, Eriksson JE. Protein phosphatase inhibition in normal and keratin 8/18 assembly-incompetent mouse strains supports a functional role of keratin intermediate filaments in preserving hepatocyte integrity. Hepatology 1998;28:116-128.
20. Ku NO, Wright TL, Terrault NA, Gish R, Omary MB. Mutation of human keratin 18 in association with cryptogenic cirrhosis. J Clin Invest 1997;99:19-23.
21. Ku NO, Gish R, Wright TL, Omary MB. Keratin 8 mutations in patients with cryptogenic liver disease. N Engl J Med 2001;344: 1580-1587.
22. Ku NO, Darling JM, Krams SM, Esquivel CO, Keeffe EB, Sibley RK, et al. Keratin 8 and 18 mutations are risk factors for developing liver disease of multiple etiologies. Proc Natl Acad Sci U S A 2003;100:6063-6068.
23. Omary MB, Ku NO, Toivola DM. Keratins: guardians of the liver. Hepatology 2002;35:251-257.
24. Morshed SA, Parveen S, Nishioka M. Antibodies to cytoskeleton antigen in autoimmune liver diseases. In: Krawitt EL, Wiesner RH, Nishioka M, eds. Autoimmune liver diseases, 2nd ed. Netherlands: Elsevier Science B.V., 1998:217-256.
25. Murota M, Nishioka M, Fujita J, Dobashi N, Wu F, Ohtsuki Y, et al. Anti-cytokeratin antibodies in sera of the patients with autoimmune hepatitis. Clin Exp Immunol 2001;125:291-299.